Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Action Pharma secures funds for critical Phase II trial as it seeks development partner

This article was originally published in Scrip

Executive Summary

Action Pharma of Denmark has secured a convertible loan of €5 million from its four investors, in addition to the €2 million loan secured at the start of the year, which will be used to finance ongoing clinical studies of its lead drug candidate AP214. AP214 is a modified DMSH-peptide analogue in Phase IIa studies for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts